Pharmacokinetics, Safety, and Tolerability of Secukinumab in Patients with Polymyalgia Rheumatica or Giant Cell Arteritis

The primary objective of this study is to evaluate the **pharmacokinetics**, safety, and tolerability of Secukinumab in patients diagnosed with **Polymyalgia Rheumatica (PMR)** and **Giant Cell Arteritis (GCA)**. Understanding the pharmacokinetics of Secukinumab in these conditions is clinically relevant as it provides insights into the drug's absorption, distribution, metabolism, and excretion, which are crucial for optimizing therapeutic regimens and ensuring patient safety. The study aims to assess how the drug behaves in the body and its potential side effects, which is essential for determining its suitability and efficacy in treating these inflammatory conditions.

The clinical trial involves a total of **38 participants** diagnosed with **polymyalgia rheumatica (PMR)** and **giant cell arteritis (GCA)**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, indicating a middle-aged to older adult demographic. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data from a diverse group, reflecting the typical patient population affected by these conditions.

The clinical trial is designed to evaluate the **pharmacokinetics**, safety, and tolerability of Secukinumab in patients diagnosed with **polymyalgia rheumatica** (PMR) or **giant cell arteritis** (GCA). This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is March 15, 2024, with an anticipated end date of July 25, 2025, indicating an overall trial duration of approximately 16 months. Participants will be involved in a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized and commence treatment, with regular follow-up visits scheduled to monitor safety, efficacy, and any adverse events. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the trial's endpoints. The expected length of participant involvement will span the entire duration of the trial unless specific conditions necessitate early termination, such as significant adverse reactions or withdrawal of consent. The trial's design ensures rigorous monitoring and data collection to achieve its objectives while maintaining participant safety and adherence to ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental or non-experimental treatments used in the study, and as such, a comprehensive description cannot be formulated.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 15, 2024, with an estimated completion date of July 25, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to rigorous standards typical of Phase 3 studies, ensuring that the efficacy assessments are conducted with scientific precision and reliability. The trial's design will likely involve validated scales, laboratory tests, or patient-reported outcomes, consistent with standard practices in clinical research, although specific tools or instruments are not mentioned. The focus will be on obtaining robust data to support the evaluation of the treatment's efficacy in the targeted medical condition.